Table 3.
Overall responses in the 99 EGFR-mutant evaluated patients
Patient population | Source (reference) | CR+PR (%) | SD (%) | PD (%) | Total |
---|---|---|---|---|---|
Chemotherapy naïve (1st line therapy) | Inoue (43) | 12 (75%) | 2 (12.5%) | 2 (12.5%) | 16 |
Asahina (44) | 12 (75%) | 1 (6%) | 3 (19%) | 16 | |
Mixed 1st and subsequent lines of therapy | Sutani (45) | 21 (78%) | 5 (18.5%) | 1 (3.5%) | 27 |
Yoshida (46) | 19 (90.5%) | 1 (4.8%) | 1 (4.8%) | 21 | |
Sunaga (47) | 16 (84%) | 3 (15%) | 0 (0%) | 19* | |
Total | 80 (80.8%) | 12 (12.1%) | 7 (7.1%) | 99 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease
in the prospective trial by Sunaga et al. (47) 21 patients were entered, however 2 discontinued treatment and only 19 were available for analysis of overall response to gefitinib therapy